Navigation Links
Icon Bioscience Completes Enrollment in Phase I Study of Novel Ophthalmic Drug Candidate
Date:8/5/2008

-Trial to Examine New Therapeutic Platform in Patients with Cystoid Macular

Edema-

SUNNYVALE, Calif., Aug. 5 /PRNewswire/ -- Icon Bioscience, Inc., (IBI), a privately held ophthalmic pharmaceutical company, announced today that enrollment has been completed in its Phase I clinical trial to assess the safety and efficacy of its lead product, IBI-20089, in patients with cystoid macular edema. This multi-site trial enrolled patients with cystoid macular edema associated with retinal vein occlusion and post operative cataract surgery.

IBI-20089 is a novel drug product based on IBI's proprietary Verisome(TM) drug delivery platform technology, which is optimally suited for application in the ophthalmic market. IBI-20089 is designed to last up to one year with a single intravitreal injection. It uniquely provides physicians the flexibility to tailor the duration of effect for a particular patient. IBI- 20089 is administered as a standard intravitreal injection without the need for additional devices or surgical procedures.

"We are pleased to have reached this important milestone. Our preliminary data confirms the safety and efficacy of our lead product, IBI-20089, as well as the versatility and flexibility of our underlying Verisome(TM) drug delivery technology," said Vernon G. Wong, MD, Founder of Icon Bioscience, Inc. "We believe IBI is creating the future standard of ophthalmic care as evidenced by the development of IBI-20089, the first of many products already in development based on the Verisome(TM) technology."

About Icon Bioscience, Inc.

Icon Bioscience, Inc. (IBI) is a privately held company focused on the development and commercialization of novel ophthalmic pharmaceuticals, based on its proprietary Verisome(TM) drug delivery platform. The Verisome(TM) drug delivery technology encompasses over twenty related but distinct novel and proprietary drug delivery systems optimally suited for application in the ophthalmic market. The nature of ophthalmic disease and the unique anatomical and physiological features of the eye, combined with the extreme fragility of the eye, dictate that identifying the correct pharmaceutical agent for a specific disease state represents only half the solution. The pharmaceutical agent must be delivered in a manner that maximizes clinical efficacy while minimizing costs and adverse effects. IBI's lead product, IBI-20089, is in Phase I clinical trials for the treatment of cystoid macular edema.

Contact: Icon Bioscience, Inc.

William S. (Sandy) White

Phone: 408-734-8188 Ext. 14

Email: sandywhite@iconbioscience.com


'/>"/>
SOURCE Icon Bioscience, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
3. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2018)... COLLEGE PARK, Md. (PRWEB) , ... August 02, 2018 , ... ... will receive up to $7.7 million over 5 years from the National Institute of ... an ongoing tick research program to understand the immune responses of ticks that contribute ...
(Date:8/2/2018)... ... August 02, 2018 , ... Although there is a wealth of advice out ... based on a generalized “best practices” approach. But now doctors and their patients have ... optimal health. , Technology exists to help people find the right diet and personalized ...
(Date:8/2/2018)... ... 01, 2018 , ... Coral Health, a leading provider of ... that will be fuelled by the Coral Health Token. After months of intensive ... commence its token sale September 28, 2018. , Founded by a team ...
Breaking Medicine Technology:
(Date:8/11/2018)... ... ... Dr. Siavash Eftekhari, Oral and Maxillofacial Surgeon at Monarch Dental® in Grapevine, ... deliver dental care in impoverished communities. Along with a team of fellow Smile ... help deliver care to over 550 individuals in need. , This outreach was hosted ...
(Date:8/9/2018)... ... , ... Thousands of US women with FDA-approved silicone gel ... The American Society of Plastic Surgeons (ASPS), The American Society for Aesthetic Plastic ... an MRI is recommended by FDA after the first three years then every ...
(Date:8/9/2018)... (PRWEB) , ... August 09, 2018 , ... ... Jim and Kathy Coover and the company’s independent distributors, customers, and employees, the ... 24 hours of fundraising, exceeding the $2 million goal. 100 percent of the ...
(Date:8/3/2018)... ... August 03, 2018 , ... Firstaid4sport have been successfully selling ... the Firstaid4sport business in the 1990's and his son in law, Michael Davison ... providers in the UK of sports medicine products, supplying professional and amateur sports ...
(Date:8/2/2018)... ... 2018 , ... Allegheny Health Network (AHN) has ... and outside the network to vital patient imaging exams, saving valuable time and ... leading hospital systems nationwide in using lifeIMAGE, which expands access to patients’ medical ...
Breaking Medicine News(10 mins):